Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
7.15
-0.15 (-2.05%)
Aug 13, 2025, 4:00 PM - Market closed
Exicure Employees
Exicure had 7 employees as of December 31, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,126,143
Market Cap
45.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
XCUR News
- 5 days ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 9 days ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 12 days ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 6 weeks ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 3 months ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire